{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "exchange": "PNK", "shortName": "CANSINO BIOLOGICS INC", "longName": "CanSino Biologics Inc.", "messageBoardId": "finmb_108945349", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 4.5, "marketState": "REGULAR", "fiftyTwoWeekHighChangePercent": -0.7450425, "fiftyTwoWeekLow": 4.5, "fiftyTwoWeekHigh": 17.65, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.53, "sharesOutstanding": 132671000, "bookValue": 26.791, "fiftyDayAverage": 5.8607, "fiftyDayAverageChange": -1.3607001, "fiftyDayAverageChangePercent": -0.23217365, "twoHundredDayAverage": 8.13029, "twoHundredDayAverageChange": -3.63029, "twoHundredDayAverageChangePercent": -0.44651422, "marketCap": 2126492928, "priceToBook": 0.16796686, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "priceHint": 4, "regularMarketChange": 0.0, "regularMarketTime": 1683036931, "regularMarketDayHigh": 4.5, "regularMarketDayRange": "4.5 - 4.5", "regularMarketDayLow": 4.5, "regularMarketVolume": 1, "regularMarketPreviousClose": 4.5, "fullExchangeName": "Other OTC", "financialCurrency": "CNY", "regularMarketOpen": 4.5, "averageDailyVolume3Month": 395, "averageDailyVolume10Day": 30, "fiftyTwoWeekLowChange": 0.0, "fiftyTwoWeekLowChangePercent": 0.0, "fiftyTwoWeekRange": "4.5 - 17.65", "fiftyTwoWeekHighChange": -13.15, "firstTradeDateMilliseconds": 1577975400000, "displayName": "CanSino Biologics", "symbol": "CASBF"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "401-420, Biomedical Park", "address2": "4th Floor 185 South Avenue TEDA West District", "city": "Tianjin", "country": "China", "phone": "400 922 2099", "fax": "022 58213677", "website": "https://www.cansinotech.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.", "fullTimeEmployees": 2291, "companyOfficers": [{"maxAge": 1, "name": "Dr. Xuefeng  Yu Ph.D.", "age": 58, "title": "Co-Founder, Chairman, CEO & GM", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Tao  Zhu Ph.D.", "age": 48, "title": "Co-Founder, Exec. Director, Deputy GM & Chief Scientific Officer", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dongxu  Qiu MBA, Ph.D.", "age": 61, "title": "Co-Founder, Exec. VP, Exec. Director & Deputy GM", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Xi  Luo", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1977, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Shou-Bai  Chao", "age": 59, "title": "Exec. Director, COO & Deputy GM", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chunlin  Xin", "title": "Sr. Director of New Technology Department", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Yonghui  Wu", "title": "VP of Marketing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Jing  Wang", "age": 41, "title": "Chief Commercial Officer, Deputy GM & Exec. Director", "yearBorn": 1981, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ming King  Chiu FCIS, FCS", "age": 45, "title": "Joint Company Sec.", "yearBorn": 1977, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 3, "boardRisk": 6, "compensationRisk": 1, "shareHolderRightsRisk": 9, "overallRisk": 4, "governanceEpochDate": 1682899200, "maxAge": 86400}}], "error": null}}